Is Intravenous Iron Treatment in Pediatric Patients Safe and Effective Enough?

Creative Commons License

Karadaş N., Töret E., Karadaş U.

GUNCEL PEDIATRI, vol.20, no.2, pp.168-173, 2022 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 2
  • Publication Date: 2022
  • Doi Number: 10.4274/jcp.2022.94940
  • Journal Name: GUNCEL PEDIATRI
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, Veterinary Science Database
  • Page Numbers: pp.168-173
  • Keywords: Iron deficiency anemia, intravenous treatment, effectivity, safety, DEFICIENCY ANEMIA, FERRIC CARBOXYMALTOSE, CHILDREN, EFFICACY, THERAPY, ADOLESCENTS, PREVENTION, PREVALENCE, DIAGNOSIS, INFANTS
  • Eskisehir Osmangazi University Affiliated: Yes

Abstract

Introduction: Iron deficiency anemia (IDA) is the most common hematological disease among infants and children. Although most of the children with IDA are treated with oral iron preparations, intravenous (IV) iron is an alternative for children with severe IDA who have difficulty in adhering to or absorbing oral iron. In this study, the reasons of IDA in patients treated with IV iron and the effectivity and safety of iron sucrose preparations in pediatric patients were evaluated.